wouldn't a doctor want to investigate the data backing a newly fda approved drug in the market before prescribing it? And if thats the case, didn't pona have superior #s in comparison to some leading drugs that are already in the market? hence the accelerated approval. wouldnt that be enough for doctors to give considerations in recommending pona sooner, rather than latter?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.